A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
A CpG-adjuvanted intranasal enterovirus 71 vaccine elicits mucosal and systemic immune responses and protects human SCARB2-transgenic mice against lethal challenge ; volume:8 ; number:1 ; day:16 ; month:7 ; year:2018 ; pages:1-11 ; date:12.2018
Scientific reports ; 8, Heft 1 (16.7.2018), 1-11, 12.2018
- Urheber
-
Lin, Yu-Li
- Beteiligte Personen und Organisationen
-
Chow, Yen-Hung
Huang, Li-Min
Hsieh, Szu-Min
Cheng, Pei-Yun
Hu, Kai-Chieh
Chiang, Bor-Luen
SpringerLink (Online service)
- DOI
-
10.1038/s41598-018-28281-5
- URN
-
urn:nbn:de:101:1-2018091821091547645502
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Lin, Yu-Li
- Chow, Yen-Hung
- Huang, Li-Min
- Hsieh, Szu-Min
- Cheng, Pei-Yun
- Hu, Kai-Chieh
- Chiang, Bor-Luen
- SpringerLink (Online service)
Ähnliche Objekte (12)
Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses
Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection
An intranasal cationic liposomal polysaccharide vaccine elicits humoral immune responses against Streptococcus pneumoniae
Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
Intranasal immunization of mice with chimera of Salmonella Typhi protein elicits protective intestinal immunity
Immunization with a fusion protein vaccine candidate generated from truncated peptides of human enterovirus 71 protects mice from lethal enterovirus 71 infections
Oral immunization with recombinant enterovirus 71 VP1 formulated with chitosan protects mice against lethal challenge
Adjuvanted infuenza vaccine dynamics
Adjuvanted influenza vaccine dynamics
An attachment glycoprotein nanoparticle elicits broadly neutralizing antibodies and protects against lethal Nipah virus infection
Broad protection with an inactivated vaccine against primary-isolated lethal enterovirus 71 infection in newborn mice
Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses
Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection
An intranasal cationic liposomal polysaccharide vaccine elicits humoral immune responses against Streptococcus pneumoniae
Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
Intranasal immunization of mice with chimera of Salmonella Typhi protein elicits protective intestinal immunity
Immunization with a fusion protein vaccine candidate generated from truncated peptides of human enterovirus 71 protects mice from lethal enterovirus 71 infections
Oral immunization with recombinant enterovirus 71 VP1 formulated with chitosan protects mice against lethal challenge
Adjuvanted infuenza vaccine dynamics
Adjuvanted influenza vaccine dynamics
An attachment glycoprotein nanoparticle elicits broadly neutralizing antibodies and protects against lethal Nipah virus infection
Broad protection with an inactivated vaccine against primary-isolated lethal enterovirus 71 infection in newborn mice
Immunization of N terminus of enterovirus 71 VP4 elicits cross-protective antibody responses
Immunogenicity of intraperitoneal and intranasal liposome adjuvanted VLP vaccines against SARS-CoV-2 infection
An intranasal cationic liposomal polysaccharide vaccine elicits humoral immune responses against Streptococcus pneumoniae
Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
Intranasal immunization of mice with chimera of Salmonella Typhi protein elicits protective intestinal immunity
Immunization with a fusion protein vaccine candidate generated from truncated peptides of human enterovirus 71 protects mice from lethal enterovirus 71 infections
Oral immunization with recombinant enterovirus 71 VP1 formulated with chitosan protects mice against lethal challenge
Adjuvanted infuenza vaccine dynamics
Adjuvanted influenza vaccine dynamics
An attachment glycoprotein nanoparticle elicits broadly neutralizing antibodies and protects against lethal Nipah virus infection